ReViral – Innovative therapies for viral diseases
ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.
The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
ReViral is an emerging UK-based biotechnology company aiming to help patients and to enlarge the antiviral market by developing novel first-in-class compounds.
The first target is Respiratory Syncytial Virus (RSV) treatment which represents a major unmet medical need in children, the elderly and the immune-compromised. The very large number of patients provide a significant commercial opportunity. As its first program, ReViral is developing a novel, highly potent, small molecule inhibitor of RSV fusion RV521 which has completed its Phase 1 clinical studies and has shown significant activity in phase 2 clinical studies in adult volunteers. RV521 is now moving towards phase 2 studies in infant and adult patients.
Location: United Kingdom, England, Stevenage
Employees: 11-50
Total raised: $99M
Founded date: 2011
Investors 5
| Date | Name | Website |
| - | Brace Phar... | bracepharm... |
| - | Andera Par... | anderapart... |
| - | OrbiMed | orbimed.co... |
| - | Perceptive... | perceptive... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.09.2020 | Series C | $44M | - |
| 01.08.2018 | Series B | $55M | New Leaf V... |
Mentions in press and media 16
| Date | Title | Description |
| 07.04.2022 | A-Rod-backed sports betting app Mojo wants to let you bet on athletes like stocks | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. Good morning, Term Sheeters. Jackson Fordyce here, filling in for Jessica. Paid Content How North... |
| 01.09.2020 | SBC company ReViral raises $44 million in Series C financing | London & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiviral therapeutics that target respiratory syncytial virus (RSV), today a... |
| 01.09.2020 | SBC company ReViral raises $44 million in Series C financing | SBC company ReViral raises $44 million in Series C financing 01-09-2020 London & Research Triangle Park, N.C. - ReViral Ltd., a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel antiv... |
| 28.08.2020 | Reviral raises $44 million in Series C financing | |
| 27.08.2020 | UK biopharma startup ReViral lands $44M Series C | CR-CP Life Science Fund, the joint VC vehicle of Charoen Pokphand Group and China Resources Capital Management, has led a $44 million investment in ReViral, a developer of antiviral therapeutics for respiratory disease. The proceeds of the ... |
| 25.08.2020 | ReViral Raises $44 Million in Series C Financing | - |
| 10.12.2018 | Cambridge companies feature in SyndicateRoom's Top 100 | Cambridge companies feature in SyndicateRoom's Top 100 10-12-2018 What are the hottest companies operating in the UK today? Investment platform SyndicateRoom has ranked the Top 100 fastest-growing businesses in the country, from geolocation... |
| 02.08.2018 | Term Sheet — Thursday, August 2 | 5 Qs WITH A DEALMAKER Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop You may know Dréan as the founder of Triago, one of the first private equity fund placement agents. His latest ven... |
| 01.08.2018 | ReViral closes $55 million Series B funding round for RSV drug | The company plans to use the funding to move its lead drug candidate, RV521, into Phase IIa studies in pediatric and adult patients, including a global pediatric study. Data from 66 patients in a placebo-controlled Phase IIa study presented... |
| 01.08.2018 | ReViral gets a $55M booster shot of cash as it expands its development work on an RSV treatment | Six months after ReViral outlined the efficacy of their respiratory syncytial virus, or RSV, treatment in healthy adults with an intranasal infection, the London-based biotech has raised a $55 million B round to take the ... |
Show more